Pricing Log in Create free account
Friday 6 November 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.

Revenue
+10.6%
EPS
−104.4%
Free cash flow
−69.3%
Total debt
+16.0%

Quarter to September 2026, against a year earlier

248.32 4.39 +1.80%
Market cap
$36.1B
P/E
104×
Fwd P/E
47.4×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Biogen Inc. (BIIB) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Biogen Inc. (BIIB) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from 1.9× (April 2025) to 11.5× (March 2015); the current reading is higher than 55% of that period. That is in line with the Drug Manufacturers General industry median of 4.1× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 2.9× 13.11%
FY2024 2.5× (44.15%)
FY2023 4.5× 12.20%
FY2022 4.0× 15.73%
FY2021 3.5× 5.90%
FY2020 3.3× (14.81%)
FY2019 3.9× (18.93%)
FY2018 4.8× (20.26%)
FY2017 6.0× 11.58%
FY2016 5.4× (21.91%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 3.8× 1.12%
Jun 2026 3.8× 29.60%
Mar 2026 2.9× 2.13%
Dec 2025 2.9× 25.78%
43 more quarters

Against its own ten years

Low 1.9× High 11.5×
Ten-year median 3.9×
Current reading's percentile 60

EV/Sales against peers

Company EV/Sales
SNY Sanofi compare 2.1×
GSK GSK PLC Sponsored ADR compare 2.9×
BMY Bristol Myers Squibb Company compare 3.2×
PFE Pfizer Inc. compare 3.4×
NVO Novo Nordisk A/S compare 3.8×
BIIB Biogen Inc. 4.1×
AZN AstraZeneca PLC compare 5.0×
GILD Gilead Sciences, Inc. compare 7.4×
AMGN Amgen Inc. compare 7.5×
Drug Manufacturers General industry median 4.1×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on BIIB